Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: Long-term follow-up (Q67694283)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1712606%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

title

Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1712606%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: Long-term follow-up (English)

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

5 November 2022

1 reference

1 reference

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

5 November 2022

author name string

D. P. Dearnaley

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1712606

5 November 2022

A. Horwich

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1712606

5 November 2022

R. A'Hern

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1712606

5 November 2022

J. Nicholls

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1712606

5 November 2022

G. Jay

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1712606

5 November 2022

W. F. Hendry

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1712606

5 November 2022

M. J. Peckham

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1712606

5 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1712606

5 November 2022

publication date

1 January 1991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1712606%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

17 September 2019

https://api.elsevier.com/content/article/PII:027753799190166B?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

https://api.elsevier.com/content/article/PII:027753799190166B?httpAccept=text/plain

5 November 2022

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

European Journal of Cancer

5 November 2022

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1712606%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1712606%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

page(s)

684-691

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1712606%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1712606%20AND%20SRC:MED&resulttype=core&format=json

The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP)

17 September 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer

5 November 2022

2

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours

5 November 2022

7

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

5 November 2022

Etoposide (VP-16-213)

10

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Epipodophylin derivative (VP 16-23) in malignant teratomas and choriocarcinomas

5 November 2022

11

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Etoposide for therapy-resistant testicular tumors.

5 November 2022

12

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Etoposide salvage therapy for refractory germ cell tumors: an update

5 November 2022

13

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

VP-16–213 salvage therapy for refractory germinal neoplasms

5 November 2022

14

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma

5 November 2022

15

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

The role of surgery in the combined management of metastases from malignant teratomas of testis

5 November 2022

16

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

What is known about tumour proliferation rates to choose between accelerated fractionation or hyperfractionation?

5 November 2022

18

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up

5 November 2022

19

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin

5 November 2022

20

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis

5 November 2022

21

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.

5 November 2022

22

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group

5 November 2022

24

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer

5 November 2022

25

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

The late effects of cis-platinum on renal function

5 November 2022

26

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

The long-term effect of cisplatin on renal function

5 November 2022

27

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Long-term toxicity of chemotherapy for testicular cancer--the cost of cure

5 November 2022

29

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Long-term sequelae of treatment for testicular germ cell tumours

5 November 2022

30

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer.

5 November 2022

31

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide

5 November 2022

32

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors

5 November 2022

33

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

The pulmonary toxicity of antineoplastic agents

5 November 2022

34

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Influence of Platinum-Induced Renal Toxicity on Bleomycin-Induced Pulmonary Toxicity in Patients with Disseminated Testicular Carcinoma

5 November 2022

35

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Changes in pulmonary function during and after bleomycin treatment in patients with testicular carcinoma

5 November 2022

36

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Children fathered by men treated with chemotherapy for testicular cancer

5 November 2022

37

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Germ cell tumour chemotherapy

5 November 2022

40

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Prognostic factors for favorable outcome in disseminated germ cell tumors

5 November 2022

42

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies

5 November 2022

43

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol

5 November 2022

44

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group study

5 November 2022

46

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Phase I studies with carboplatin at the Royal Marsden Hospital

5 November 2022

47

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

cis-Diammine-1, 1-cyclobutane dicarboxylate platinum II (carboplatin) in the treatment of testicular germ-cell tumours: a preliminary report.

5 November 2022

48

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma

5 November 2022

49

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors

5 November 2022

51

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

The management of advanced testicular teratoma

5 November 2022

53

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients

5 November 2022

54

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.

5 November 2022

58

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors.

5 November 2022

60

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

Hemopoietins in oncology: factoring out myelosuppression

5 November 2022

61

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90166-B

5 November 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1712606%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

1 reference